Journal of Cancer Epidemiology

Journal of Cancer Epidemiology / 2013 / Article

Review Article | Open Access

Volume 2013 |Article ID 965212 |

Gabriella Pellegriti, Francesco Frasca, Concetto Regalbuto, Sebastiano Squatrito, Riccardo Vigneri, "Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors", Journal of Cancer Epidemiology, vol. 2013, Article ID 965212, 10 pages, 2013.

Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors

Academic Editor: Thomas E. Rohan
Received27 Feb 2013
Accepted15 Apr 2013
Published07 May 2013


Background. In the last decades, thyroid cancer incidence has continuously and sharply increased all over the world. This review analyzes the possible reasons of this increase. Summary. Many experts believe that the increased incidence of thyroid cancer is apparent, because of the increased detection of small cancers in the preclinical stage. However, a true increase is also possible, as suggested by the observation that large tumors have also increased and gender differences and birth cohort effects are present. Moreover, thyroid cancer mortality, in spite of earlier diagnosis and better treatment, has not decreased but is rather increasing. Therefore, some environmental carcinogens in the industrialized lifestyle may have specifically affected the thyroid. Among potential carcinogens, the increased exposure to medical radiations is the most likely risk factor. Other factors specific for the thyroid like increased iodine intake and increased prevalence of chronic autoimmune thyroiditis cannot be excluded, while other factors like the increasing prevalence of obesity are not specific for the thyroid. Conclusions. The increased incidence of thyroid cancer is most likely due to a combination of an apparent increase due to more sensitive diagnostic procedures and of a true increase, a possible consequence of increased population exposure to radiation and to other still unrecognized carcinogens.

1. Introduction

Thyroid cancer is the most common endocrine cancer (approximately 1.0%–1.5% of all new cancers diagnosed each year in the USA) [1], and its incidence has continuously increased in the last three decades all over the world. This trend is present on every continent (Table 1) except Africa [2], where detection is possibly insufficient. The increasing incidence is indicated by the annual percent change (APC) that in the USA was 2.4% from 1980 to 1997 and 6.6% from 1997 to 2009 (both genders) (Cancer of The Thyroid-SEER Stat Fact Sheets, available at accessed on December 10, 2012). Based on recent data, thyroid cancer is the fifth most common cancer in women [3], and in Italy, it is the second most frequent cancer in women below 45 years of age [4]. Only in few countries (Norvay, Sweden) thyroid cancer incidence is decreased [2].

CountrySourceYearsVariation of incidence (APC)

Australia[27] (Patients aged 15–30 years)1982


China (Shanghai)[30] 1983

Spain[10] (Only PTCs)197820019.4 2.6

APC: annual percent change.
*Average annual percent increase.
Percent temporal change (% increase) in the indicated period.
Incidence increase in the indicated period.

Genetic factors, environmental influences, and access to medical care can easily explain the high variability (up to nearly tenfold) in the thyroid cancer incidence by geographic area and ethnicity.

Recent reports indicated a similar age-specific trends by racial/ethnic groups. Although the lowest rates of thyroid cancer are observed in blacks, the greatest rate of papillary thyroid cancer acceleration occurs in black females [5]. Male and female annual percent change was 6.3% and 7.1% for white patients, 4.3% and 8.4% for black, 4.2% and 6.7% for Hispanic and 3.4% and 6.4% for Asian/PI (Pacific Islander) patients respectively [5].

In any case, the continuously increasing rate of thyroid cancer is independent of the underlying incidence rates [2]. The increase is nearly exclusively due to increases in the incidence of the papillary histotype, with no significant change for the follicular, medullary, or anaplastic histotypes (Figure 1). The increase mainly regards small tumors, although large tumors have also increased [6, 7].

In spite of the steadily increased incidence, thyroid cancer mortality is reported stable at approximately 0.5 cases per 100,000 persons [8]. At variance with most tumors (including breast, colon-rectum, lung, and prostate cancer) whose mortality has decreased in the last two decades, thyroid cancer mortality rate is not decreased, but rather slightly increased. Indeed, the jointpoint trend reported by SEER for the period 1988–2009 (Cancer of The Thyroid-SEER Stat Fact Sheets, available at, accessed on December 10, 2012) indicates a significant increase of thyroid cancer mortality (+0.8% annual percent change, APC), primarily in males. This increase in mortality rate occurred in spite of early diagnosis and better treatment of high risk thyroid cancers. The divergence between the sharp increase in incidence and mortality, therefore, is probably less relevant than first recognized also considering that the indolent behavior of most thyroid cancers would affect mortality only many years after the increase in incidence.

Explanations for the worldwide increase of thyroid cancer incidence are controversial. Some experts believe that the increased number of new cancers is due to the increased diagnostic intensity [8, 9]. Other experts believe that a true increase, due to environment and lifestyle changes, is also a likely possibility [6, 7, 1013]. The problem is of medical and socioeconomic relevance. Since most individuals with differentiated thyroid cancer will do well, the risk of “overdiagnosis” has been hypothesized. Overdiagnosis detects diseases that will not affect patient health and survival. Detecting these diseases not only will confer little benefit to the patient (“pseudodisease”) [14] but may also cause potential damage in terms of avoidable distress, possible adverse consequences of unnecessary treatment, and increasing economic cost. Thyroid cancer can easily fall within the condition of “overdiagnosis” because it progresses slowly, causes symptoms only when advanced, and rarely causes death.

The economic cost of overdiagnosis in a thyroid cancer patient can range from hundreds to thousands dollars, depending on the extent of the examinations performed and the complexity of the intervention and followup [15]. To prevent these costs and the inconveninences of unnecessary treatment many proposals have been recently advanced, including not submitting to cytological examination nodules ≤1.0 cm  that do not have additional risk factors (Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer, available at, accessed on December 12, 2012) and the “wait and see” approach without treatment for microcarcinomas [16]. Recent studies suggest that the treatment and follow-up costs can be reduced in low-risk tumors by selective, simplified procedures [17, 18]. At present this is the most rational approach, based on the judgment of various prognostic factors that affect the patient outcome. Risk stratification, however, is based on clinical characteristics that leave a margin of uncertainty, not only for recurrent disease but also for the possibility of metastatic and deadly evolution. Although very low, this possibility provides the physician and the patient with a difficult dilemma. In fact, even when considering only microcarcinomas, extracapsular extension, lymph node metastases, and/or extrathyroid extension are found at presentation in a percentage variable from 15% to 30% [19] (Cancer of The Thyroid-SEER Stat Fact Sheets, available at accessed on December 10, 2012). Distant metastases are also present in a small percentage of cases (1%–3%). These characteristics are predictors of cancer related recurrence and mortality. We should also consider that the large majority of patients with a microcarcinoma (78%), when offered observation without surgery, opted for immediate surgery [16].

Therefore, a better understanding of the cause(s) of increased thyroid cancer incidence rate and improved risk stratification, using specific biological and molecular markers to accurately estimate whether a subclinical thyroid malignancy will remain stationary or will progress to an adverse outcome, is a priority to avoid overtreatment.

2. Review

2.1. Has the Thyroid Cancer Incidence Truly Increased?
2.1.1. Arguments in Favor of an Apparent Increase

The more frequent use of sensitive diagnostic procedures, including ultrasound, Doppler examination, imaging techniques like CT scan, MRI or PET scanning, and biochemical markers, has increased the detection of many types of cancer. As far as the thyroid is concerned, ultrasound and cytology examinations have identified an increasing number of small, asymptomatic thyroid cancers. Ultrasound use, in particular, has boosted the detection of small thyroid nodules that would have gone undetected in clinical practice (only 40% of thyroid nodules smaller than 1.5 cm in maximum diameter are discovered during a physical examination) [21]. The high prevalence of thyroid nodules, affecting up to 30%–50% of the population in late adulthood [21], constitutes an enormous reservoir of potential cancer lesions to be investigated. Moreover, incidental thyroid nodules (including malignant nodules) today are frequently identified after diagnostic procedures for different primary diseases. Doppler examination of the neck vessels and other imaging procedures like PET scan, for instance, have increased the detection of incidental thyroid tumors [22, 23]. Finally, the incidental discovery of preclinical thyroid tumors at pathology examination may be more frequent because of the increased use of enlarged surgical excision (total or subtotal thyroidectomy) for nonmalignant thyroid diseases [9]. In support of an increased screening effect is also the observation that thyroid cancer is positively associated with high levels of income, education, and other socioeconomic indicators of healthcare access [24]. This factor, however, should have also increased the detection of other tumors whose incidence has not increased.

The diffuse use of sensitive diagnostic procedures may have affected the incidence of cancers in the thyroid more than in other sites because thyroid cancer has an indolent progression and may remain unrecognized in the preclinical stage for years or decades, as confirmed by the observation of a high frequency (2.8%–39%) of small thyroid cancers during autopsies [25, 26]. The observation that most thyroid cancers (over 80%) are smaller than two centimeters at the time of diagnosis [8] is consistent with the possibility that increased surveillance and more sensitive diagnostic procedures are detecting cancers that were also present in the past but went undiscovered (Table 2).

(A) The increase is apparent (not more cancers but more detection)
 (i) Widespread diffusion of advanced medical procedures (ultrasounds and fine needle aspiration biopsy)
 (ii) The increased incidence concerns mainly microcarcinomas
 (iii) Increased detection of “incidental,” microcarcinomas because
  (1) total thyroidectomies for benign lesions are more frequent
  (2) pathological examinations are more detailed
  (3) incidental discovery of nodules at diagnostic examination for other diseases is frequent
 (iv) High frequency of undiagnosed, asyntomatic small thyroid cancers at autopsy
 (v) Improved accuracy of cancer registration
(B) The increase is true (more cancers because of changes in the risk factors)
 (i) Large tumors are also increased
 (ii) The incidence of large size and advanced stage cancers is not decreased, as expected when early diagnosis is more frequent
 (iii) Only the papillary histotype of thyroid cancer is increased
 (iv) Increased incidence is not proportionally distributed for age and gender (secular trend is greater for females and a birth cohort pattern is present)
 (v) Improved accuracy of cancer registration should have produced similar effects also for other tumors
 (vi) Mortality rate
  (1) stable mortality rate may result from early diagnosis and better treatment counteracting the effect of the increased cancer number
  (2) thyroid cancer progression is very slow and increased incidence would affect mortality only after decades
  (3) recent data indicate that mortality is increasing, specially in males

2.1.2. Arguments in Favor of a True Increase

When improved detection is the only cause, the increase of small, early stage tumors should be accompanied by a progressive decline of larger and more advanced tumors. The thyroid cancer increase, while most prominent for small tumors, occurred across all tumor sizes and stages, suggesting that increased detection is not the only cause [6, 10]. From 1992 to 1995, in the USA, approximately 50% of the thyroid cancer incidence increase was due to tumors ≤1.0 cm, 30% to tumors 1.1–2.0 cm, and 20% to tumors >2.0 cm [6]. In another study, the incidence rate increased for tumors <2.0 cm and >4.0 cm in size but not for tumors of medium size (2.0–4.0 cm) [7]. In Spain, from 1978 to 2001, the thyroid cancer incidence increased equally in microcarcinomas and in larger tumors [10]. Recently, an increased incidence for thyroid cancers of all stages (localized, regional, and distant staged disease) has been confirmed (Figure 1) [11]. The increased incidence of thyroid cancers of large volume and advanced stages, usually clinically apparent, can hardly be explained by increased detection.

Moreover, the thyroid cancer increase almost exclusively occurred for papillary tumors (Figure 1), while improved detection should have affected all histotypes. Recently, analysing the incidence patterns in SEER data in the United States during 1980–2009, Aschebrook-Kilfoy et al. described a modest increase in age-adjusted follicular thyroid cancer rates (Figure 1) [20].

Although improved detection can more effectively favor the identification of small, nonaggressive PTC which are the most indolent tumors, the small difference in cancer-related mortality between the papillary (approximately 7% at 10 years) and the follicular (approximately 15%) histotypes indicates that increased detection should have also affected the incidence of the follicular histotype.

We cannot exclude, therefore, that specific carcinogens might have favored the molecular abnormalities typical of papillary cancer, a hypothesis supported by the increasing incidence of BRAF-positive papillary tumors over time [32, 33] (Table 3).


ExogenousX-raysMedical imaging (dental X-ray and CT scans)
131INuclear medicine procedures
IodineDiet, iodine prophylaxis, BRAFV600E (?)
NitrateWater and diet
Westernized lifestyle and environmental Undiscovered carcinogens
pollutantsBisphenol A (BPA), polychlorinated biphenyls (PCB), polybrominated diphenyl ethers (PBDEs)


EndogenousTSHThyroid growth stimulation
Autoimmuneincreased TSH and oxidative stress
Obesity and insulin resistanceHyperinsulinemia promotes cancer, but this factor is not specific for the thyroid

Finally, when increased detection is the only cause, the cancer increase is expected to occur in all age and gender categories. Indeed, the age-adjusted incidence rates of thyroid cancer have increased among females more than males (158% versus 106%, resp.) with a clear birth cohort pattern, possibly reflecting changes in risk factors [34]. Although a different screening intensity according to age and gender cannot be excluded, the different secular trend in the two genders and the birth cohort effect suggest that increased detection is not the only cause of the increased incidence of thyroid cancer (Table 3). Also the age-specific trends by race do not support a detection effect as the reason for the increasing incidence.

2.2. Risk Factors That May Contribute to the Increased Thyroid Cancer Incidence
2.2.1. Radiation

Exposure to ionizing radiation is a well-documented risk factor for cancer. The thyroid may be irradiated more than other tissues because of its position in the body and its ability to concentrate iodine.

During the last 25 years, the individual radiation dose has doubled in the USA [35], from approximately 3 mSv/year in 1980 to 6 mSv/year in 2006. This variation is mainly due to medical diagnostic procedures [35]. Medical and dental diagnostic examinations have specifically increased thyroid exposure to X-rays [36]. CT scans, although accounting for only 15% of all radiological diagnostic procedures in the USA, provide more than 50% of the radiation dose absorbed by patients [37]. Because one-third of all CT scans are performed in the head/neck region, the thyroid is particularly exposed to radiation. Moreover, the use of iodinated contrast agents increases the radiation absorbed by the thyroid by up to 35% because iodine blocks photons, increasing the local radiation energy [38].

The thyroid is very radiosensitive at a young age. Children exposed to radiation frequently develop papillary thyroid cancer (PTC) as shown by the peak of thyroid cancers observed after the Chernobyl accident, when approximately  Bq of 131I were released into the atmosphere. On that occasion, the thyroid received a dose 500- to 1000-times higher than the rest of the body, and approximately 4,000 thyroid cancer cases were reported [39]. The role of CT scans in increasing the risk of cancer in children is already documented: CT scans delivering a cumulative dose of 50–60 mGy almost triple the risk of leukaemia and brain cancer [40]. Direct evidence of CT radiation effect on the incidence of thyroid cancer in children is not available. However, risk projections can be used to estimate the potential cancer burden from CT scans on the basis of the age at scan and the type of scan. The increasing number of CT scans during childhood was hypothesized to increase the number of thyroid malignancies by up to 390 per million exposed individuals [41] and CT scans carried out in the USA in 2007 have been estimated to potentially cause about 1000 future thyroid cancers [42].

A recent analysis indicated that thyroid cancer risk in children exposed to head and neck radiation is inversely correlated to the age, decreasing to a nonstatistically significant level by age 15 [43]. However, a carcinogenic effect of radiation on the adult thyroid population cannot be excluded, as indicated by the increased incidence of thyroid cancer among female survivors of the atomic bomb that were older than 20 years at the time of the explosion [44]. Moreover, a recent report indicates that dental X-rays may increase thyroid cancer risk also in adults [45]. As a consequence, thyroid shielding has been recently recommended by the American Thyroid Association during diagnostic dental X-rays both in children and adults (American Thyroid Association (ATA) Issues Policy Statement on Minimizing Radiation Exposure from Medical, Dental Diagnostics, available at radiation-exposure-from-medical-dental-diagnostics/ accessed on December 10, 2012).

Another specific source of thyroid irradiation is thyroid imaging with 131I that has been largely used for the diagnosis of thyroid diseases. Thyroid scans reached 13% of all nuclear medicine examinations in 1973 [46] and thereafter decreased to the present rate of less than 1% with 131I substituted by the less-dangerous [46]. The therapeutic use of 131I for hyperthyroidism, however, has continued or even increased, and a small increase in thyroid cancer has been observed in these adult patients [47]. Other cancer types (stomach, kidney, and breast) are also increased in patients treated with RAI for hyperthyroidism [48]. A recent meta-analysis concluded that the use of RAI for hyperthyroidism effectively increases the risk of thyroid (RR 1.99, 95% CI: 0.92–1.33), kidney (RR 1.70, 95% CI: 1.15–2.51), and stomach cancer (RR 1.11, 95% CI: 0.92–1.33) and a dose effect was also observed for the thyroid at diagnostic doses >1 Gy [49].

Finally, radiotherapy for head and neck malignancies is an additional source of thyroid irradiation. Indeed, in a cohort of childhood cancer survivors, 7.5% of all secondary malignancies were thyroid cancers [50]. Increased exposure to radiation, therefore, may have contributed to the increased incidence of thyroid cancer.

2.2.2. TSH Levels and Iodine Intake

Iodine deficiency causes an increase of thyroid-stimulating hormone (TSH), a major growth factor for thyroid follicular cells. Animal experiments demonstrated a clear increase of thyroid cancer after prolonged iodine deficiency leading to increased TSH. However, this effect is not demonstrated in human residents of iodine-deficient areas [51, 52]. Iodine intake is known to influence the thyroid cancer histotype distribution, rather than the overall incidence, with more follicular and fewer papillary carcinomas in iodine-deficient areas [53]. When iodine prophylaxis is introduced, average serum TSH decreases and the papillary : follicular ratio increases [54, 55]. The iodine-associated shift from a follicular to a papillary histotype may be due to the frequency of the BRAF(V600E) mutation, a typical molecular alteration in PTC. BRAF-positive PTCs were significantly more frequent in Chinese regions with a high iodine intake than in control areas [56]. Although a causal relationship between iodine intake and BRAF mutation is not proven, the worldwide increase of iodine intake and the parallel increase in the prevalence of BRAF-positive PTCs [32] is in agreement with a possible role of increased iodine intake in the increased PTC incidence.

2.2.3. TSH Levels and Autoimmune Thyroiditis

A major role of TSH in thyroid cancer progression is indicated by the decreased recurrence rate and improved survival in thyroid cancer patients treated with TSH-suppressive L-T4 [57]. However, a role of TSH in inducing thyroid cancer, documented in rodents, is controversial in humans. A recent study indicates that, at both univariate and multivariate analyses, the risk to have a thyroid cancer and also to have a cancer in an advanced stage is increased in patients with higher TSH serum level [58]. This correlation was confirmed in fine needle aspiration biopsies in a large series of more than 10,000 patients with thyroid nodules: the risk of malignancy was higher in patients with a higher TSH serum level [59]. Conversely, the risk of cancer was reduced in hyperthyroid patients with autonomous thyroid nodules and a low serum TSH. A similar correlation was observed also in L-T4-treated patients having serum TSH lower than untreated patients [60]. These data suggest that TSH levels, indepedently of the underlying mechanism, are positively correlated with thyroid cancer risk.

There is no evidence that serum TSH levels have increased in the population in the last decades. However, the frequency of chronic autoimmune Hashimoto’s thyroiditis, the most common cause of primary hypothyroidism in the westernized world, has increased in the last two decades, paralleling the increased iodine intake [61]. Autoimmune thyroiditis might influence cancer risk not only by increasing TSH levels but also because the autoimmune process per se, via the production of proinflammatory cytokines and oxidative stress [62], might enhance thyroid tumorigenesis. However, the PTC frequency in patients with autoimmune thyroiditis is related to serum TSH but not to the presence of antithyroid antibodies, and when these patients are treated with LT-4 to prevent a TSH increase, the risk of thyroid cancer is no longer increased [60].

2.2.4. Thyroid Nodules

Whether the prevalence of thyroid cancer is different in thyroid glands with a single nodule (SN) versus multinodular goiter (MNG) remains uncertain.

The prevalence of malignancy in SN has been estimated at 5% [63]. As indicated in the recent guidelines for the management of thyroid nodules patients with multiple thyroid nodules have the same risk of malignancy as those with solitary nodules [6467]. Individual studies, however, provide cancer prevalence in patients with MNG that are lower (4.1%) [68] or higher (18%) [69]. A recent meta-analysis supported the inference that thyroid cancer is less frequent in MNG than in SN, although this finding appears to hold true mostly outside the United States, in iodine-deficient populations [70].

2.2.5. Body Weight and Insulin Resistance

A strong correlation between obesity and cancer risk and mortality has been demonstrated for several malignancies [71]. A pooled analysis of five prospective studies indicated that also the risk of thyroid cancer is greater in obese subjects [72].

As obesity is a multifactorial syndrome, the contribution to cancerogenesis of each single obesity feature (type of adiposity, metabolic derangement, insulin resistance, etc.) is unclear. A recent study supports the possibility that insulin resistance and hyperinsulinemia (a typical feature of obesity) rather than metabolic derangement may be a risk factor for thyroid cancer [73]. Insulin regulates thyroid gene expression and stimulates thyrocyte proliferation, differentiation, and transformation. Insulin resistance was present in 50% of PTC patients versus 10% of matched controls [74], and BMI at the time of diagnosis was directly related to thyroid cancer risk in females [75]. Hyperinsulinemia, therefore, may be a risk factor for thyroid cancer, but its effect on the thyroid should be similar to that observed on other organs where cancer incidence has not increased [71]. The pandemia of obesity that characterizes the last decades, therefore, may have contributed to thyroid cancer increase but whether a specific effect on the thyroid is present and what is the underlying mechanism is unknown.

2.2.6. Diet, Lifestyle, and Environmental Pollutants

The influences of diet, lifestyle, and pollution on thyroid cancer initiation have never been studied carefully. The evidences of a possible effect of nutrient/food or environmental pollutants on thyroid cancer are weak and not confirmed. Studies aimed at identifying cancer risk factors belonging to diet and lifestyle have provided controversial results [76] because food and drinks have a great number of different constituents (many unmeasured or highly variable) and also because dietary intake and lifestyle may significantly change in the same individual over time.

In addition to iodine itself, dietetic factors that interfere with iodine organification and thyroid hormone synthesis, such as cruciferous vegetables, could also affect thyroid cancer risk [77]. This possibility, however, has never been demonstrated. Some industrialized food contaminants, for instance nitrates, can compete with iodine uptake by the thyroid and can behave as potential thyroid function disruptors and carcinogens. Nitrate is a frequent contaminant of drinking water in areas of intense agricultural industry and is found at high levels in some vegetables and processed food [78]. A high average nitrate level in water supplies is associated with an increased risk of thyroid cancer (highest versus lowest quartile, RR = 2.9 [1.0–8.1] [79].

In the last decades, the population has been more exposed to environmental pollutants like asbestos, benzene, formaldehyde, pesticides, bisphenol A (BPA), polychlorinated biphenyls (PCB), and polyhalogenated aromatic hydrocarbons (PHAHs), all compounds that may act as either genotoxic or nongenotoxic carcinogens. Particularly polybrominated diphenyl ethers (PBDEs) may induce abnormal thyroid cell proliferation, favoring a precancerous state [80]. At present, however, no causal correlation has been established between enviromental pollutants and thyroid cancer in humans. Out of 80,000 chemicals present in products on the US market, only a few hundred have been tested for carcinogenicity, and their possible combinations provide an indefinite number of potential carcinogens. It is possible that some products have a specific carcinogenic effect on the thyroid, either directly or acting as endocrine disruptors [81]. We and others [52, 82, 83] observed that the volcanic environment may be associated with an increase in thyroid cancer incidence. In the Mt. Etna volcanic area, where thyroid cancer incidence rate is more than doubled in respect to the rest of Sicily [52], only the papillary histotype is increased and both micro- and macrocarcinomas are augmented, reflecting the worldwide pattern of thyroid cancer increase. Nonanthropogenic pollutants are increased in drinking water derived from the volcanic aquifer and in the urine of the local population, confirming the increased population exposure to the pollutants, mainly heavy metals (R.V., unpublished data). A possible cause-effect relationship between these compounds and thyroid cancer is under study. If this relationship is present, it may help to unravel some of the environmental factors that favor the worldwide increase of papillary thyroid cancer.

3. Summary and Conclusions

The reason(s) for the worldwide increase in thyroid cancer are stil unclear. The cause is most likely multifactorial and the increased detection rate certainly represents part of the phenomenon, since small tumors are predominately increased. A true increase, however, is also likely as indicated by the increase also of large tumors, the exclusive increase of the papillary histotype only, and the differences in gender and age cohort increase. Also the lack of mortality decrease, in spite of earlier diagnosis and more efficacious treatment, supports the possibility that an increasing number thyroid cancers occurs at present.

Increased exposure to radiation is the most likely contributing factor but also other environmental carcinogens can contribute. Although at present we have no solid evidence of a carcinogenic effect of diet and lifestyle changes and/or of environmental pollutants on the thyroid, the possibility that undiscovered environmental carcinogens might be responsible for an increased thyroid cancer incidence cannot be excluded. In particular, exposure to some chemicals during intrauterine life and early childhood, with possible epigenetic changes, might affect thyroid cell propension to mutagenesis. Further studies are warranted to investigate the potential carcinogens and their mechanism of action in order to introduce preventive measures and control the continuous increase of thyroid cancer.

Conflict of Interests

No competing financial interests exist.

Authors’ Contribution

Gabriella Pellegriti and Francesco Frasca have equally contributed to this paper.


This work was supported by Grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy) and from the Ministry of the University (PRIN 2012) to R. Vigneri.


  1. M. P. Curado, B. Edwards, H. R. Shin et al., Cancer Incidence in Five Continents, vol. 9 of IARC Scientific Publications, No. 160, IARC, Lyon, France, 2007.
  2. B. A. Kilfoy, T. Zheng, T. R. Holford et al., “International patterns and trends in thyroid cancer incidence, 1973–2002,” Cancer Causes and Control, vol. 20, no. 5, pp. 525–531, 2009. View at: Publisher Site | Google Scholar
  3. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at: Publisher Site | Google Scholar
  4. L. dal Maso, M. Lise, P. Zambon et al., “Incidence of thyroid cancer in Italy, 1991–2005: time trends and age-period-cohort effects,” Annals of Oncology, vol. 22, no. 4, pp. 957–963, 2011. View at: Publisher Site | Google Scholar
  5. B. Aschebrook-Kilfoy, E. L. Kaplan, B. C. Chiu, P. Angelos, and R. H. Grogan, “The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States,” Annals of Surgical Oncology, 2013. View at: Publisher Site | Google Scholar
  6. L. Enewold, K. Zhu, E. Ron et al., “Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 3, pp. 784–791, 2009. View at: Publisher Site | Google Scholar
  7. W. D. T. Kent, S. F. Hall, P. A. Isotalo, R. L. Houlden, R. L. George, and P. A. Groome, “Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease,” Canadian Medical Association Journal, vol. 177, no. 11, pp. 1357–1361, 2007. View at: Publisher Site | Google Scholar
  8. L. Davies and H. G. Welch, “Increasing incidence of thyroid cancer in the United States, 1973–2002,” Journal of the American Medical Association, vol. 295, no. 18, pp. 2164–2167, 2006. View at: Publisher Site | Google Scholar
  9. S. Grodski, T. Brown, S. Sidhu et al., “Increasing incidence of thyroid cancer is due to increased pathologic detection,” Surgery, vol. 144, no. 6, pp. 1038–1043, 2008. View at: Publisher Site | Google Scholar
  10. A. Rego-Iraeta, L. F. Pérez-Méndez, B. Mantinan, and R. V. Garcia-Mayor, “Time trends for thyroid cancer in northwestern spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma,” Thyroid, vol. 19, no. 4, pp. 333–340, 2009. View at: Publisher Site | Google Scholar
  11. E. P. Simard, E. M. Ward, R. Siegel, and A. Jemal, “Cancers with increasing incidence trends in the United States: 1999 through 2008,” CA: A Cancer Journal For Clinicians, vol. 62, no. 2, pp. 118–128, 2012. View at: Publisher Site | Google Scholar
  12. A. Y. Chen, A. Jemal, and E. M. Ward, “Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005,” Cancer, vol. 115, no. 16, pp. 3801–3807, 2009. View at: Publisher Site | Google Scholar
  13. B. Aschebrook-Kilfoy, M. H. Ward, M. M. Sabra, and S. S. Devesa, “Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006,” Thyroid, vol. 21, no. 2, pp. 125–134, 2011. View at: Publisher Site | Google Scholar
  14. H. G. Welch and P. C. Albertsen, “Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005,” Journal of the National Cancer Institute, vol. 101, no. 19, pp. 1325–1329, 2009. View at: Publisher Site | Google Scholar
  15. M. Schlumberger, I. Borget, C. Nascimento, M. Brassard, and S. Leboulleux, “Treatment and follow-up of low-risk patients with thyroid cancer,” Nature Reviews Endocrinology, vol. 7, no. 10, pp. 625–628, 2011. View at: Publisher Site | Google Scholar
  16. Y. Ito and A. Miyauchi, “Is surgery necessary for papillary thyroid microcarcinomas?” Nature Reviews Endocrinology, vol. 8, no. 1, p. 9, 2012. View at: Google Scholar
  17. E. K. Alexander and P. R. Larsen, “Radioiodine for thyroid cancer—is less more?” The New England Journal of Medicine, vol. 366, no. 18, pp. 1732–1733, 2012. View at: Publisher Site | Google Scholar
  18. M. Schlumberger, B. Catargi, I. Borget et al., “Strategies of radioiodine ablation in patients with low-risk thyroid cancer,” The New England Journal of Medicine, vol. 366, no. 18, pp. 1663–1673, 2012. View at: Google Scholar
  19. G. Pellegriti, C. Scollo, G. Lumera, C. Regalbuto, R. Vigneri, and A. Belfiore, “Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 3713–3720, 2004. View at: Publisher Site | Google Scholar
  20. B. Aschebrook-Kilfoy, R. Grogan, M. Ward, E. Kaplan, and S. Devesa, “Follicular thyroid cancer incidence patterns in the United States, 1980–2009,” Thyroid, 2013. View at: Publisher Site | Google Scholar
  21. E. L. Mazzaferri, “Management of a solitary thyroid nodule,” The New England Journal of Medicine, vol. 328, no. 8, pp. 553–559, 1993. View at: Publisher Site | Google Scholar
  22. I. L. Nilsson, F. Arnberg, J. Zedenius, and A. Sundin, “Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/computed tomography: practical management algorithm,” World Journal of Surgery, vol. 35, no. 12, pp. 2691–2697, 2011. View at: Publisher Site | Google Scholar
  23. M. Yun, T. W. Noh, A. Cho et al., “Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 7, pp. 3182–3188, 2010. View at: Publisher Site | Google Scholar
  24. B. L. Sprague, S. Warren Andersen, and A. Trentham-Dietz, “Thyroid cancer incidence and socioeconomic indicators of health care access,” Cancer Causes and Control, vol. 19, no. 6, pp. 585–593, 2008. View at: Publisher Site | Google Scholar
  25. H. R. Harach, K. O. Franssila, and V. M. Wasenius, “Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study,” Cancer, vol. 56, no. 3, pp. 531–538, 1985. View at: Google Scholar
  26. E. L. Mazzaferri, “Managing thyroid microcarcinomas,” Yonsei Medical Journal, vol. 53, no. 1, pp. 1–14, 2012. View at: Publisher Site | Google Scholar
  27. F. A. Haggar, D. B. Preen, G. Pereira, C. D. Holman, and K. Einarsdottir, “Cancer incidence and mortality trends in Australian adolescents and young adults, 1982–2007,” BMC Cancer, vol. 12, no. 1, p. 151, 2012. View at: Publisher Site | Google Scholar
  28. S. Liu, R. Semenciw, A. M. Ugnat, and Y. Mao, “Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects,” British Journal of Cancer, vol. 85, no. 9, pp. 1335–1339, 2001. View at: Publisher Site | Google Scholar
  29. L. F. Ellison and K. Wilkins, “Canadian trends in cancer prevalence,” Health Reports, vol. 23, no. 1, pp. 7–16, 2012. View at: Google Scholar
  30. Y. Wang and W. Wang, “Increasing incidence of thyroid cancer in shanghai, China, 1983–2007,” Asia-Pacific Journal of Public Health, 2012. View at: Publisher Site | Google Scholar
  31. M. Colonna, A. V. Guizard, C. Schvartz et al., “A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000),” European Journal of Cancer, vol. 43, no. 5, pp. 891–900, 2007. View at: Publisher Site | Google Scholar
  32. A. Mathur, W. Moses, R. Rahbari et al., “Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study,” Cancer, vol. 117, no. 19, pp. 4390–4395, 2011. View at: Publisher Site | Google Scholar
  33. C. Romei, L. Fugazzola, E. Puxeddu et al., “Modifications in the papillary thyroid cancer gene profile over the last 15 years,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 9, pp. E1758–E1765, 2012. View at: Google Scholar
  34. C. Zhu, T. Zheng, B. A. Kilfoy et al., “A birth cohort analysis of the incidence of papillary thyroid cancer in the united states, 1973–2004,” Thyroid, vol. 19, no. 10, pp. 1061–1066, 2009. View at: Publisher Site | Google Scholar
  35. F. A. Mettler Jr., M. Bhargavan, B. R. Thomadsen et al., “Nuclear Medicine Exposure in the United States, 2005–2007: preliminary results,” Seminars in Nuclear Medicine, vol. 38, no. 5, pp. 384–391, 2008. View at: Publisher Site | Google Scholar
  36. F. A. Mettler Jr., P. W. Wiest, J. A. Locken, and C. A. Kelsey, “CT scanning: patterns of use and dose,” Journal of Radiological Protection, vol. 20, no. 4, pp. 353–359, 2000. View at: Publisher Site | Google Scholar
  37. O. W. Linton and F. A. Mettler, “National conference on dose reduction in CT, with an emphasis on pediatric patients,” American Journal of Roentgenology, vol. 181, no. 2, pp. 321–329, 2003. View at: Google Scholar
  38. S. R. Baker and W. A. Bhatti, “The thyroid cancer epidemic: is it the dark side of the CT revolution?” European Journal of Radiology, vol. 60, no. 1, pp. 67–69, 2006. View at: Publisher Site | Google Scholar
  39. D. Williams, “Radiation carcinogenesis: lessons from Chernobyl,” Oncogene, vol. 27, supplement 2, pp. S9–S18, 2008. View at: Publisher Site | Google Scholar
  40. M. S. Pearce, J. A. Salotti, M. P. Little et al., “Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study,” The Lancet, vol. 380, no. 9840, pp. 499–4505, 2012. View at: Publisher Site | Google Scholar
  41. M. Mazonakis, A. Tzedakis, J. Damilakis, and N. Gourtsoyiannis, “Thyroid dose from common head and neck CT examinations in children: is there an excess risk for thyroid cancer induction?” European Radiology, vol. 17, no. 5, pp. 1352–1357, 2007. View at: Publisher Site | Google Scholar
  42. A. Berrington de González, M. Mahesh, K. P. Kim et al., “Projected cancer risks from computed tomographic scans performed in the United States in 2007,” Archives of Internal Medicine, vol. 169, no. 22, pp. 2071–2077, 2009. View at: Publisher Site | Google Scholar
  43. E. Ron, J. H. Lubin, R. E. Shore et al., “Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies,” Radiation Research, vol. 141, no. 3, pp. 259–277, 1995. View at: Publisher Site | Google Scholar
  44. D. B. Richardson, “Exposure to ionizing radiation in adulthood and thyroid cancer incidence,” Epidemiology, vol. 20, no. 2, pp. 181–187, 2009. View at: Publisher Site | Google Scholar
  45. A. Memon, S. Godward, D. Williams, I. Siddique, and K. Al-Saleh, “Dental x-rays and the risk of thyroid cancer: a case-control study,” Acta Oncologica, vol. 49, no. 4, pp. 447–453, 2010. View at: Publisher Site | Google Scholar
  46. E. Ron, “Cancer risks from medical radiation,” Health Physics, vol. 85, no. 1, pp. 47–59, 2003. View at: Publisher Site | Google Scholar
  47. J. A. Franklyn, P. Maisonneuve, M. C. Sheppard, J. Betteridge, and P. Boyle, “Mortality after the treatment of hyperthyroidism with radioactive iodine,” The New England Journal of Medicine, vol. 338, no. 11, pp. 712–718, 1998. View at: Publisher Site | Google Scholar
  48. S. Metso, A. Auvinen, H. Huhtala, J. Salmi, H. Oksala, and P. Jaatinen, “Increased cancer incidence after radioiodine treatment for hyperthyroidism,” Cancer, vol. 109, no. 10, pp. 1972–1979, 2007. View at: Publisher Site | Google Scholar
  49. T. T. Hieu, A. W. Russell, R. Cuneo et al., “Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis,” Endocrine-Related Cancer, vol. 19, no. 5, pp. 645–655, 2012. View at: Publisher Site | Google Scholar
  50. P. Black, A. Straaten, and P. Gutjahr, “Secondary thyroid carcinoma after treatment for childhood cancer,” Medical and Pediatric Oncology, vol. 31, no. 2, pp. 91–95, 1998. View at: Google Scholar
  51. L. dal Maso, C. Bosetti, C. la Vecchia, and S. Franceschi, “Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors,” Cancer Causes and Control, vol. 20, no. 1, pp. 75–86, 2009. View at: Publisher Site | Google Scholar
  52. G. Pellegriti, F. de Vathaire, C. Scollo et al., “Papillary thyroid cancer incidence in the volcanic area of sicily,” Journal of the National Cancer Institute, vol. 101, no. 22, pp. 1575–1583, 2009. View at: Publisher Site | Google Scholar
  53. U. Feldt-Rasmussen, “Iodine and cancer,” Thyroid, vol. 11, no. 5, pp. 483–486, 2001. View at: Google Scholar
  54. B. Dijkstra, R. S. Prichard, A. Lee et al., “Changing patterns of thyroid carcinoma,” Irish Journal of Medical Science, vol. 176, no. 2, pp. 87–90, 2007. View at: Publisher Site | Google Scholar
  55. H. R. Harach, D. A. Escalante, and A. Onativia, “Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis,” Acta Endocrinologica, vol. 108, no. 1, pp. 55–60, 1985. View at: Google Scholar
  56. H. Guan, M. Ji, R. Bao et al., “Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 5, pp. 1612–1617, 2009. View at: Publisher Site | Google Scholar
  57. E. L. Mazzaferri, “Papillary and follicular thyroid cancer: selective therapy,” Comprehensive Therapy, vol. 7, no. 5, pp. 6–14, 1981. View at: Google Scholar
  58. M. R. Haymart, D. J. Repplinger, G. E. Leverson et al., “Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 3, pp. 809–814, 2008. View at: Publisher Site | Google Scholar
  59. E. Fiore, T. Rago, M. A. Provenzale et al., “Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role,” Endocrine-Related Cancer, vol. 16, no. 4, pp. 1251–1260, 2009. View at: Publisher Site | Google Scholar
  60. E. Fiore, T. Rago, M. A. Provenzale et al., “L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients,” Endocrine-Related Cancer, vol. 17, no. 1, pp. 231–239, 2010. View at: Publisher Site | Google Scholar
  61. D. Repplinger, A. Bargren, Y. W. Zhang, J. T. Adler, M. Haymart, and H. Chen, “Is hashimoto's thyroiditis a risk factor for papillary thyroid cancer?” Journal of Surgical Research, vol. 150, no. 1, pp. 49–52, 2008. View at: Publisher Site | Google Scholar
  62. M. Khatami, “Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity,” Cell Biochemistry and Biophysics, vol. 55, no. 2, pp. 55–79, 2009. View at: Publisher Site | Google Scholar
  63. L. Hegedus, “Clinical practice. The thyroid nodule,” The New England Journal of Medicine, vol. 351, no. 17, pp. 1764–1771, 2004. View at: Publisher Site | Google Scholar
  64. E. Marqusee, C. B. Benson, M. C. Frates et al., “Usefulness of ultrasonography in the management of nodular thyroid disease,” Annals of Internal Medicine, vol. 133, no. 9, pp. 696–700, 2000. View at: Google Scholar
  65. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at: Publisher Site | Google Scholar
  66. E. Papini, R. Guglielmi, A. Bianchini et al., “Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-doppler features,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 5, pp. 1941–1946, 2002. View at: Publisher Site | Google Scholar
  67. M. C. Frates, C. B. Benson, P. M. Doubilet et al., “Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3411–3417, 2006. View at: Publisher Site | Google Scholar
  68. V. Mathai, J. Idikula, A. S. Fenn, and A. Nair, “Do long-standing nodular goitres result in malignancies?” Australian and New Zealand Journal of Surgery, vol. 64, no. 3, pp. 180–182, 1994. View at: Google Scholar
  69. Y. Erbil, U. Barbaros, A. Salmaslioǧlu et al., “Effect of thyroid gland volume in preoperative detection of suspected malignant thyroid nodules in a multinodular goiter,” Archives of Surgery, vol. 143, no. 6, pp. 558–563, 2008. View at: Publisher Site | Google Scholar
  70. J. P. Brito, A. J. Yarur, L. J. Prokop, B. McIver, M. H. Murad, and V. M. Montori, “Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis,” Thyroid, vol. 23, no. 4, pp. 449–455, 2013. View at: Publisher Site | Google Scholar
  71. P. Vigneri, F. Frasca, L. Sciacca, L. Frittitta, and R. Vigneri, “Obesity and cancer,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 16, no. 1, pp. 1–7, 2006. View at: Publisher Site | Google Scholar
  72. C. M. Kitahara, E. A. Platz, L. E. Beane Freeman et al., “Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 3, pp. 464–472, 2011. View at: Publisher Site | Google Scholar
  73. M. Almquist, D. Johansen, T. Bjorge et al., “Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can),” Cancer Causes Control, vol. 22, no. 5, pp. 743–751, 2011. View at: Google Scholar
  74. J. N. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, and H. Niepomniszcze, “Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma,” Metabolic Syndrome and Related Disorders, vol. 7, no. 4, pp. 375–380, 2009. View at: Publisher Site | Google Scholar
  75. T. Mijović, J. How, M. Pakdaman et al., “Body mass index in the evaluation of thyroid cancer risk,” Thyroid, vol. 19, no. 5, pp. 467–472, 2009. View at: Google Scholar
  76. W. J. Mack, S. Preston-Martin, L. Dal Maso et al., “A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea,” Cancer Causes and Control, vol. 14, no. 8, pp. 773–785, 2003. View at: Publisher Site | Google Scholar
  77. E. Peterson, P. De, and R. Nuttall, “BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review,” PLoS One, vol. 7, no. 1, Article ID e29177, 2012. View at: Google Scholar
  78. B. A. Kilfoy, Y. Zhang, Y. Park et al., “Dietary nitrate and nitrite and the risk of thyroid cancer in the NIH-AARP diet and health study,” International Journal of Cancer, vol. 129, no. 1, pp. 160–172, 2011. View at: Publisher Site | Google Scholar
  79. M. H. Ward, B. A. Kilfoy, P. J. Weyer, K. E. Anderson, A. R. Folsom, and J. R. Cerhan, “Nitrate intake and the risk of thyroid cancer and thyroid disease,” Epidemiology, vol. 21, no. 3, pp. 389–395, 2010. View at: Publisher Site | Google Scholar
  80. Y. Zhang, G. L. Guo, X. Han et al., “Do polybrominated diphenyl ethers (PBDE) increase the risk of thyroid cancer?” Bioscience Hypotheses, vol. 1, no. 4, pp. 195–199, 2008. View at: Publisher Site | Google Scholar
  81. D. C. Christiani, “Combating environmental causes of cancer,” The New England Journal of Medicine, vol. 364, no. 9, pp. 791–793, 2011. View at: Publisher Site | Google Scholar
  82. E. Arnbjornsson, A. Arnbjornsson, and A. Olafsson, “Thyroid cancer incidence in relation to volcanic activity,” Archives of Environmental Health, vol. 41, no. 1, pp. 36–40, 1986. View at: Google Scholar
  83. T. M. Kung, W. L. Ng, and J. B. Gibson, “Volcanoes and carcinoma of the thyroid: a possible association,” Archives of Environmental Health, vol. 36, no. 5, pp. 265–267, 1981. View at: Google Scholar

Copyright © 2013 Gabriella Pellegriti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

32037 Views | 10046 Downloads | 465 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.